Design: Randomized, Double-Blind, Placebo-Controlled Crossover Trial Purpose: To assess the effects of raloxifene (a synthetic estrogen receptor modulator) on blood vessel performance in healthy post-menopausal women. Raloxifene is commonly prescribed for osteoporosis prevention in post-menopausal women; however, cardioprotective effects have not been studied to date.
Further Study Details:
The 20 women enrolled in this study were assigned to 2 treatments – raloxifene (60 mg) or placebo daily for 6 weeks. Following each treatment assignment, participants underwent BARS and laser Doppler velocimetry (LDV) testing.
Findings:
Treatment with raloxifene was shown to improved blood vessel reactivity as compared to placebo, thus suggesting that raloxifene may have a cardioprotective effect in this population. Additionally, raloxifene was not associated with any more side effects than placebo.
Eligibility:
Healthy, post-menopausal woman not taking hormone replacement therapy
Yale-Griffin Prevention Research Center